S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
Log in

Brookline Capital Management Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from pubilc media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

DateBrokerageActionCompany
Name		RatingPrice
Target		Impact on
Share Price		Actions
8/20/2019Brookline Capital ManagementReiteratesAtreca (BCEL)BuyHighView Rating Details  Share on Twitter  Share on StockTwits
8/19/2019Brookline Capital ManagementReiteratesSCYNEXIS (SCYX)BuyHighView Rating Details  Share on Twitter  Share on StockTwits
8/15/2019Brookline Capital ManagementInitiatesVaxart (VXRT)Buy $6.00LowView Rating Details  Share on Twitter  Share on StockTwits
7/25/2019Brookline Capital ManagementReiteratesCelsion (CLSN)BuyMediumView Rating Details  Share on Twitter  Share on StockTwits
7/24/2019Brookline Capital ManagementReiteratesChiasma (CHMA)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
7/29/2019Brookline Capital ManagementInitiatesProgenics Pharmaceuticals (PGNX)Buy $10.00LowView Rating Details  Share on Twitter  Share on StockTwits
7/29/2019Brookline Capital ManagementInitiatesVeru (VERU)Buy $12.00HighView Rating Details  Share on Twitter  Share on StockTwits
7/29/2019Brookline Capital ManagementInitiatesHeat Biologics (HTBX)Buy$8.00 -> $8.00HighView Rating Details  Share on Twitter  Share on StockTwits
7/29/2019Brookline Capital ManagementInitiatesCellectar Biosciences (CLRB)Buy$6.00 -> $6.00HighView Rating Details  Share on Twitter  Share on StockTwits
7/24/2019Brookline Capital ManagementReiteratesArcturus Therapeutics (ARCT)BuyHighView Rating Details  Share on Twitter  Share on StockTwits
5/10/2019Brookline Capital ManagementReiteratesQ BioMed (QBIO)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
2/6/2019Brookline Capital ManagementReiteratesChiasma (CHMA)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
1/4/2019Brookline Capital ManagementReiteratesSCYNEXIS (SCYX)BuyHighView Rating Details  Share on Twitter  Share on StockTwits
11/27/2018Brookline Capital ManagementReiteratesRexahn Pharmaceuticals (REXN)BuyN/AView Rating Details  Share on Twitter  Share on StockTwits
11/20/2018Brookline Capital ManagementReiteratesCelsion (CLSN)BuyMediumView Rating Details  Share on Twitter  Share on StockTwits
11/20/2018Brookline Capital ManagementReiteratesCellectar Biosciences (CLRB)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
9/27/2018Brookline Capital ManagementReiteratesArcturus Therapeutics (ARCT)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
8/1/2018Brookline Capital ManagementReiteratesHeat Biologics (HTBX)BuyLowView Rating Details  Share on Twitter  Share on StockTwits
8/1/2018Brookline Capital ManagementReiteratesHistogenics (HSGX)BuyMediumView Rating Details  Share on Twitter  Share on StockTwits
7/27/2018Brookline Capital ManagementDowngradesTonix Pharmaceuticals (TNXP)Buy -> HoldLowView Rating Details  Share on Twitter  Share on StockTwits
6/26/2018Brookline Capital ManagementReiteratesProteon Therapeutics (PRTO)BuyMediumView Rating Details  Share on Twitter  Share on StockTwits
5/1/2018Brookline Capital ManagementReiteratesTonix Pharmaceuticals (TNXP)BuyLowView Rating Details  Share on Twitter  Share on StockTwits

This page was last refreshed on Tuesday at 09:06 PM ET.

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  17,640 (Vote Outperform)
Underperform Votes:  24,444 (Vote Underperform)
Total Votes:  42,084
MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recmomendations will underperform the S&P 500 over the long term. You may vote once every thirty days.
See Also:
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel